Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)

e.g. "Sirolimus", "アダリムマブ", "MAP2K"

ABCDEFGH I JKLMNOPQRSTUVWXYZother

84 / 286 pathways

No. KEGG PATHWAY   💬 Info on mouse-over
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES
💬 Info on mouse-over
KEGG DRUG
💬 Info on mouse-over
DrugBank 指定難病告示番号
💬 Info on mouse-over
1 Adipocytokine signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
2 African trypanosomiasis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
4 Allograft rejection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
5 Alzheimer disease 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
6 Alzheimer disease 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
7 Alzheimer disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
8 Amoebiasis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
9 Amphetamine addiction 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
10 Amphetamine addiction 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
11 Amyotrophic lateral sclerosis 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
12 Amyotrophic lateral sclerosis 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
13 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
14 Antifolate resistance 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
15 Antigen processing and presentation 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
16 Apoptosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
17 Asthma 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
18 Axon guidance 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
19 Axon guidance 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
20 B cell receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
21 B cell receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
22 C-type lectin receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
23 C-type lectin receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
24 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
25 Calcium signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
26 Calcium signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
27 Cellular senescence 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
28 Cellular senescence 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
29 cGMP-PKG signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
30 cGMP-PKG signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
31 Chagas disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
32 Coronavirus disease - COVID-19 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
33 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
34 Dilated cardiomyopathy 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
35 Dopaminergic synapse 💬
3件: PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
36 Dopaminergic synapse 💬
3件: PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
37 Epstein-Barr virus infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
38 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
39 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
40 Glucagon signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
41 Glucagon signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
42 Glutamatergic synapse 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
43 Glutamatergic synapse 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
44 Graft-versus-host disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
45 Hematopoietic cell lineage 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
46 Hepatitis B 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
47 Hepatitis C 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
48 Herpes simplex virus 1 infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
49 Human cytomegalovirus infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
50 Human cytomegalovirus infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
51 Human cytomegalovirus infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
52 Human immunodeficiency virus 1 infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
53 Human immunodeficiency virus 1 infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
54 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
55 Human papillomavirus infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
56 Human T-cell leukemia virus 1 infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
57 Human T-cell leukemia virus 1 infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
58 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
59 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
60 IL-17 signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
61 Inflammatory bowel disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
62 Influenza A 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
63 Insulin resistance 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
64 Kaposi sarcoma-associated herpesvirus infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
65 Kaposi sarcoma-associated herpesvirus infection 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
66 Legionellosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
67 Leishmaniasis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
68 Long-term potentiation 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
69 Long-term potentiation 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
70 Malaria 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
71 MAPK signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
72 MAPK signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
73 MAPK signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
74 mTOR signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
75 Natural killer cell mediated cytotoxicity 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
76 Natural killer cell mediated cytotoxicity 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
77 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
78 Necroptosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
79 NF-kappa B signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
80 NOD-like receptor signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
81 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
82 Oocyte meiosis 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
83 Oocyte meiosis 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
84 Osteoclast differentiation 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
85 Osteoclast differentiation 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
86 Osteoclast differentiation 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
87 Oxytocin signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
88 Oxytocin signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
89 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
90 Pathways of neurodegeneration - multiple diseases 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
91 Pathways of neurodegeneration - multiple diseases 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
92 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
93 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
94 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
95 Pertussis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
96 Prion disease 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
97 Prion disease 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
98 Prion disease 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
99 Proteoglycans in cancer 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
100 Renin secretion 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
101 Renin secretion 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
102 Rheumatoid arthritis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
103 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
104 Salmonella infection 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
105 Shigellosis 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
106 Sphingolipid signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
107 Systemic lupus erythematosus 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
108 T cell receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
109 T cell receptor signaling pathway 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
110 T cell receptor signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
111 TGF-beta signaling pathway 💬
1件: TNF 💬 D02597 💬 Adalimumab 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
112 Th1 and Th2 cell differentiation 💬
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus 32件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬
113 Th1 and Th2 cell differentiation 💬